Nektar Therapeutics’s recently made public that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $10403.0 on Feb 19 ’25. In the deal valued at $1.01 per share,10,300 shares were sold. As a result of this transaction, Zalevsky Jonathan now holds 316,604 shares worth roughly $0.19 million.
Then, Wilson Mark Andrew sold 11,040 shares, generating $11,150 in total proceeds. Upon selling the shares at $1.01, the Chief Legal Officer now owns 324,292 shares.
Before that, ROBIN HOWARD W sold 23,774 shares. Nektar Therapeutics shares valued at $24,012 were divested by the President & CEO at a price of $1.01 per share. As a result of the transaction, ROBIN HOWARD W now holds 1,086,901 shares, worth roughly $0.65 million.
Jefferies upgraded its Nektar Therapeutics [NKTR] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who increased its forecast for the stock in mid March from “a Perform” to “an Outperform”. B. Riley Securities began covering NKTR with “Buy” recommendation on January 08, 2025. H.C. Wainwright started covering the stock on December 10, 2024. It rated NKTR as “a Buy”.
Price Performance Review of NKTR
On Monday, Nektar Therapeutics [NASDAQ:NKTR] saw its stock fall -2.23% to $0.60. Over the last five days, the stock has gained 23.14%. Nektar Therapeutics shares have fallen nearly -35.06% since the year began. Nevertheless, the stocks have fallen -61.78% over the past one year. While a 52-week high of $1.93 was reached on 01/07/25, a 52-week low of $0.43 was recorded on 04/09/25. SMA at 50 days reached $0.7790, while 200 days put it at $1.0844.
Levels Of Support And Resistance For NKTR Stock
The 24-hour chart illustrates a support level at 0.5741, which if violated will result in even more drops to 0.5444. On the upside, there is a resistance level at 0.6435. A further resistance level may holdings at 0.6832. The Relative Strength Index (RSI) on the 14-day chart is 40.72, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0436, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 57.08%. Stochastics %K at 32.58% indicates the stock is a holding.
How much short interest is there in Nektar Therapeutics?
A steep rise in short interest was recorded in Nektar Therapeutics stocks on 2025-03-31, growing by 1.15 million shares to a total of 7.77 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 6.62 million shares. There was a rise of 14.75%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 04, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $7 price target.
